RCUS - Arcus Biosciences, Inc.

QQQ $ 615.11 $ -4.04 (-0.65 %)

DIA $ 470.25 $ 0.57 (0.12 %)

SPY $ 672.36 $ -0.79 (-0.12 %)

TLT $ 90.13 $ 0.15 (0.17 %)

GLD $ 362.19 $ -1.27 (-0.35 %)

Previous Close

$ 19.83

Open

$ 19.70

Bid

$ 19.50 x 1

Ask

$ 21.20 x 57

Day's Range

$ 19.69 - $ 20.54

52 Week Range

$ 6.50 - $ 22.11

Volume

2,362,303

Average Volume

Market Cap

2.14B

Beta (5Y Monthly)

$ 1.40

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	10-28-2025	09-30-2025	10-Q
2	08-06-2025	06-30-2025	10-Q
3	05-06-2025	03-31-2025	10-Q
4	02-25-2025	12-31-2024	10-K
5	11-06-2024	09-30-2024	10-Q
6	08-08-2024	06-30-2024	10-Q
7	05-08-2024	03-31-2024	10-Q
8	02-21-2024	12-31-2023	10-K
9	11-07-2023	09-30-2023	10-Q
10	08-07-2023	06-30-2023	10-Q
11	05-09-2023	03-31-2023	10-Q
12	02-28-2023	12-31-2022	10-K
13	11-02-2022	09-30-2022	10-Q
14	08-03-2022	06-30-2022	10-Q
15	05-09-2022	03-31-2022	10-Q
16	02-23-2022	12-31-2021	10-K
17	11-08-2021	09-30-2021	10-Q
18	08-05-2021	06-30-2021	10-Q
19	05-05-2021	03-31-2021	10-Q
20	02-25-2021	12-31-2020	10-K
21	11-05-2020	09-30-2020	10-Q
22	08-06-2020	06-30-2020	10-Q
23	05-05-2020	03-31-2020	10-Q
24	03-05-2020	12-31-2019	10-K
25	11-05-2019	09-30-2019	10-Q
26	08-06-2019	06-30-2019	10-Q
27	05-02-2019	03-31-2019	10-Q
28	03-05-2019	12-31-2018	10-K
29	11-08-2018	09-30-2018	10-Q
30	08-06-2018	06-30-2018	10-Q
31	05-09-2018	03-31-2018	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Reported Earlier, Arcus Biosciences Announ...
10/31/2025 07:48:34

Arcus Biosciences Announces Public Offerin...
10/30/2025 20:27:53

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated mo...

Goldman Sachs Maintains Neutral on Arcus B...
10/30/2025 15:19:15

Goldman Sachs analyst Salveen Richter maintains Arcus Biosciences (NYSE:RCUS) with a Neutral and raises the price target fro...

Citigroup Maintains Buy on Arcus Bioscienc...
10/29/2025 19:50:53

Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $54 ...

Analyst Expectations For Arcus Biosciences...
10/29/2025 11:45:28

HC Wainwright & Co. Maintains Buy on Arcus...
10/29/2025 11:03:38

HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target ...

Arcus Biosciences Q3 EPS $(1.27) Beats $(1...
10/28/2025 20:39:51

Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.27) per share which beat the analyst consensus estimate of $(1.3...

Wells Fargo Maintains Overweight on Arcus ...
10/20/2025 13:36:48

Wells Fargo analyst Eva Fortea Verdejo maintains Arcus Biosciences (NYSE:RCUS) with a Overweight and raises the price target...

Reported Sunday, Taiho Pharmaceutical Secu...
10/20/2025 06:59:26

Citigroup Maintains Buy on Arcus Bioscienc...
10/13/2025 17:47:25

Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $47 ...

gilead-sciencesarcus-biosciences-investigational-cancer-drug-shows-overall-survival-of-around-27-months

Gilead Sciences/Arcus Biosciences' Investi...
10/13/2025 14:33:57

Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab combinatio...

Reported Earlier, Arcus Biosciences Report...
10/13/2025 06:30:41

First overall survival (OS) results from Arm A1 of the Phase 2 EDGE-Gastric study will be presented on October 18 at the Europe...

Truist Securities Reiterates Buy on Arcus ...
10/07/2025 14:15:40

Truist Securities analyst Asthika Goonewardene reiterates Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price targ...

why-is-arcus-biosciences-stock-trading-higher-on-monday

Why Is Arcus Biosciences Stock Trading Hig...
10/06/2025 18:23:52

Arcus Biosciences reports casdatifan monotherapy data in renal cancer, showing a 35% response rate and median progression-free ...

Arcus Biosciences Announces New Monotherap...
10/06/2025 12:12:58

Casdatifan data were better on every efficacy measure evaluated, across all four monotherapy cohorts (n=121) of the Phase 1/1b ...

macys-increases-fy2025-outlook-joins-rev-group-healthequity-alphabet-and-wellness-and-other-big-stocks-moving-higher-on-wednesday

Macy's Increases FY2025 Outlook, Joins REV...
09/03/2025 14:10:50

jim-cramer-recommends-this-energy-stock-but-dont-bank-it-all-on-arcus

Jim Cramer Recommends This Energy Stock, B...
08/14/2025 12:07:49

On CNBC's Mad Money Lightning Round, Jim Cramer endorsed buying Uranium Energy and called Arcus Biosciences a speculative p...

gilead-sciences-lifts-annual-outlook-as-yeztugo-launch-nears

Gilead Sciences Lifts Annual Outlook As Ye...
08/08/2025 14:55:24

Gilead raised its 2025 earnings and sales outlook after posting better-than-expected Q2 results, led by strong HIV and oncology...

Wells Fargo Maintains Overweight on Arcus ...
08/07/2025 14:43:58

Wells Fargo analyst Eva Fortea Verdejo maintains Arcus Biosciences (NYSE:RCUS) with a Overweight and lowers the price target...

Arcus Biosciences Q2 EPS $0.00 Beats $(1.1...
08/06/2025 20:11:02